Polyrizon (PLRZ) Competitors $1.39 -0.49 (-26.06%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. LGVN, CMMB, NAII, RLMD, FNCH, CING, VYNE, CYCC, AYTU, and BLRXShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Longeveron (LGVN), Chemomab Therapeutics (CMMB), Natural Alternatives International (NAII), Relmada Therapeutics (RLMD), Finch Therapeutics Group (FNCH), Cingulate (CING), VYNE Therapeutics (VYNE), Cyclacel Pharmaceuticals (CYCC), Aytu BioPharma (AYTU), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. Its Competitors Longeveron Chemomab Therapeutics Natural Alternatives International Relmada Therapeutics Finch Therapeutics Group Cingulate VYNE Therapeutics Cyclacel Pharmaceuticals Aytu BioPharma BioLineRx Polyrizon (NASDAQ:PLRZ) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Which has preferable earnings & valuation, PLRZ or LGVN? Polyrizon has higher earnings, but lower revenue than Longeveron. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/A-$1.54MN/AN/ALongeveron$2.39M10.56-$15.97M-$6.28-0.27 Do institutionals and insiders hold more shares of PLRZ or LGVN? 10.0% of Longeveron shares are held by institutional investors. 11.2% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is PLRZ or LGVN more profitable? Polyrizon has a net margin of 0.00% compared to Longeveron's net margin of -760.72%. Polyrizon's return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A Longeveron -760.72%-85.07%-70.74% Does the media favor PLRZ or LGVN? In the previous week, Polyrizon had 1 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Polyrizon and 2 mentions for Longeveron. Polyrizon's average media sentiment score of 0.40 beat Longeveron's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer PLRZ or LGVN? Longeveron has a consensus target price of $8.67, suggesting a potential upside of 412.82%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryLongeveron beats Polyrizon on 7 of the 13 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.41M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E RatioN/A20.8627.9419.95Price / SalesN/A246.06396.5882.68Price / CashN/A41.9636.1958.45Price / Book0.008.308.635.82Net Income-$1.54M-$55.19M$3.24B$258.42M7 Day Performance43.36%5.07%3.22%1.94%1 Month Performance93.06%17.61%10.72%12.02%1 Year PerformanceN/A7.03%34.94%20.80% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.39-26.1%N/AN/A$7.41MN/A0.00N/ANews CoverageGap DownLGVNLongeveron2.799 of 5 stars$1.46-0.7%$8.67+493.6%-40.2%$21.94M$2.23M-0.2320CMMBChemomab Therapeutics2.2041 of 5 stars$1.14-0.9%$8.50+645.6%-10.9%$21.69MN/A-1.5020Positive NewsNAIINatural Alternatives International0.6266 of 5 stars$3.43+0.3%N/A-37.0%$21.13M$113.80M-2.47290Positive NewsRLMDRelmada Therapeutics4.5457 of 5 stars$0.61-4.1%$5.00+724.7%-82.0%$20.98MN/A-0.2410FNCHFinch Therapeutics GroupN/A$12.50-2.0%N/A+866.9%$20.47MN/A-1.42190CINGCingulate2.5934 of 5 stars$4.72+4.4%$26.00+450.8%+1,437.0%$20.04MN/A-0.5620VYNEVYNE Therapeutics2.1933 of 5 stars$1.26-2.3%$6.25+396.0%-30.6%$19.62M$500K-1.2730CYCCCyclacel Pharmaceuticals0.9804 of 5 stars$8.20-33.5%N/A-96.5%$19.54M$40K-0.0114Gap UpHigh Trading VolumeAYTUAytu BioPharma3.766 of 5 stars$2.32+6.9%$10.00+331.0%-5.4%$19.48M$81M-3.22160News CoveragePositive NewsBLRXBioLineRx2.0608 of 5 stars$4.60+1.8%$26.00+465.2%-85.9%$19.27M$28.94M-0.5240 Related Companies and Tools Related Companies Longeveron Alternatives Chemomab Therapeutics Alternatives Natural Alternatives International Alternatives Relmada Therapeutics Alternatives Finch Therapeutics Group Alternatives Cingulate Alternatives VYNE Therapeutics Alternatives Cyclacel Pharmaceuticals Alternatives Aytu BioPharma Alternatives BioLineRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
